Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on EBIQUITY PLC. We currently have 10 research reports from 2 professional analysts.
|10Mar17 15:30||RNS||Holding(s) in Company|
|26Jan17 07:00||RNS||Pre-close trading statement|
|02Dec16 12:15||RNS||Deferred Consideration/Issue of Ordinary Shares|
|11Nov16 14:48||RNS||Holding(s) in Company|
|14Oct16 12:30||RNS||Re Directorate|
|28Sep16 07:00||RNS||Interim Results|
|09Sep16 07:00||RNS||Appointment of CFO and Director|
Frequency of research reports
Research reports on
Pick-up in activity
27 Jan 17
Ebiquity’s FY16 trading update points to 9% revenue growth (6% currency) and mid-single digit profit growth in operating and earnings. FY17 has started well with a noticeable pick up in new business activity and improved visibility; we leave our forecasts unchanged. We believe EBQ is in a strong position to execute to the growth acceleration plan presented in September 2016 and consider the 10x FY17 P/E rating unchallenging.
Small Cap Breakfast
26 Jan 17
Rainbow Rare Earths has published a prospectus. It has raised $8m to fast-track fully permitted high grade Gakara ‘rare earths’ project to production in Burundi. Intends to join the Standard List of the LSE. Impact healthcare REIT— Intends to float on the main market. Seeks to raise £160m to acquire a portfolio of up to 58 care homes. Expected Admission 7 March. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
Capitalising on its strengths
28 Sep 16
Along with the release of its (in line) interim results, management has presented its new strategy. This will involve the roll-out of the fast-growing MPO services in more markets, and investment in technology enablement across all divisions as well as in organisational processes. Initial investment means a reduction to FY17 EPS forecasts. However, Ebiquity is building on strong foundations and we believe it is in a good positon to execute its plan, which should result in a higher-quality business with a more robust longer-term growth profile.
16 Mar 17
4imprint (FOUR): 6% dividend yield for a growth stock? (BUY) | Cambridge Cognition* (COG): Amgen uses CANTAB technology in trial (CORP) | Seeing Machines* (SEE): H1 results show steady operational progress (CORP) | Allergy Therapeutics (AGY): Pollinex Quattro Birch Ph III EU trial starts (BUY) | Capital Drilling* (CAPD): FY results in line, with turnaround in exploration activity (CORP)
M&A coming to a company near you?
16 Mar 17
Markets have retained their relative strength over the last fortnight. We have seen a mixed reaction to the Budget last week, the passing of the Brexit Bill earlier in the week and the first interest rate hike by the Federal Reserve in the US yesterday. Against this backdrop, we have seen some notable M&A activity across a range of sectors which may move down the market capitalisation scale. We now face an extended period of heightened speculation but “no running commentary” regarding Brexit in the UK after Article 50 is triggered at the end of the month.
6% dividend yield for a growth stock?
16 Mar 17
4imprint’s proven operating model continues to steadily gain market share from a low base. Capital requirements are low, acquisitions unlikely, pension risk significantly reduced and, hence, future cash flow is likely to be returned to shareholders. We expect the current $22m net cash balance to be retained, providing a cushion against any macro downturns, and dividend growth to continue to match EPS, supplemented by special dividends when net cash builds (possibly every other year). As such, the free cash flow yield, 5.1% in FY2018E 5.8% in FY 2019E, is a proxy for the dividend yield, highly attractive in our view for a proven growth stock.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
10 Mar 17
We have run our new quantitative Slide Rule over the Support Services sector. Of the c.500 stocks we have ranked on a Quality, Value, Growth and Momentum basis in the small to mid-cap space, 21 Support Services stocks appear in the top 100. Fulcrum leads the pack, ranked no. 6 out of 500 (and not coincidentally our top pick for the year), closely followed by Brainjuicer (no.7), Sanne (no.8), Learning Technologies (no. 12) and Next Fifteen (no.16). These stocks have high ROCE on both an EBIT and cash basis, strong growth prospects, earnings and share price momentum and valuations that, in this context, remain attractive. At the other end of the spectrum, HSS, Management Consulting, Serco, Mitie and Lakehouse appear towards the bottom of the rankings. Strong returns could, of course, be made if any of these turn their fortunes around, and management has been changed at Lakehouse, Serco and Mitie.